NDAINTRAVENOUSSOLUTION
Approved
Nov 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ULTRA-TECHNEKOW V4 (technetium tc-99m) by Curium Pharma is radiopharmaceutical activity [moa]. First approved in 1973.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRA-TECHNEKOW V4 is a technetium Tc-99m radiopharmaceutical diagnostic agent administered intravenously to enable imaging and functional assessment across multiple organ systems. It works through radiopharmaceutical activity, emitting gamma radiation that allows visualization of tissue perfusion, organ function, and pathology. This is a foundational nuclear medicine imaging tool used in cardiology, oncology, and other specialties.
LOE Approaching
LOE-stage product with stable positioning (30% competitive pressure) suggests defensive, cost-management focus rather than growth-oriented expansion roles.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ULTRA-TECHNEKOW V4 roles emphasize regulatory compliance, market defense, and operational efficiency in a stable, LOE-stage diagnostic market. Career growth is modest; opportunities center on cost management, formulary protection, and physician relationship management rather than product innovation or geographic expansion.
Regulatory Affairs Specialist
Worked on ULTRA-TECHNEKOW V4 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.